Alpha Cognition (NASDAQ:ACOG) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Alpha Cognition (NASDAQ:ACOG) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Separately, HC Wainwright lowered their price target on shares of Alpha Cognition from $20.00 to $18.00 and set a “buy” rating for the company in a report on Monday, October 20th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $18.00.

Alpha Cognition Stock Down 0.7%

Alpha Cognition stock opened at $5.90 on Friday. The stock has a 50-day simple moving average of $7.22 and a 200 day simple moving average of $8.43. The stock has a market capitalization of $128.27 million, a price-to-earnings ratio of -4.31 and a beta of 2.62. Alpha Cognition has a 12-month low of $3.75 and a 12-month high of $11.54.

Alpha Cognition (NASDAQ:ACOG) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.13. The company had revenue of $2.84 million for the quarter, compared to the consensus estimate of $3.21 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ACOG. Geode Capital Management LLC bought a new stake in Alpha Cognition in the second quarter valued at about $112,000. Massar Capital Management LP acquired a new position in shares of Alpha Cognition during the 2nd quarter worth about $116,000. Berkshire Asset Management LLC PA increased its stake in shares of Alpha Cognition by 50.7% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 17,824 shares of the company’s stock valued at $116,000 after acquiring an additional 6,000 shares during the last quarter. Zullo Investment Group Inc. acquired a new stake in shares of Alpha Cognition in the 3rd quarter valued at approximately $127,000. Finally, Two Sigma Investments LP bought a new position in Alpha Cognition during the 3rd quarter worth approximately $148,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.